MedTrace Logo

Pharmacokinetics and Safety of DWJ1451 in Healthy Adults

NCT04819932 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-03-29

No results posted yet for this study

Summary

Amlodipine, olmesartan, total ezetimibe, rosuvastatin AUCt, Cmax

Conditions

  • Healthy

Interventions

DRUG

DWJ1451

DWC202008 DWC202009

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-13
Primary Completion
2021-03-13
Completion
2021-04-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04819932 on ClinicalTrials.gov